Krystal Biotech diskutieren
Krystal Biotech
WKN: A2JH2F / Symbol: KRYS / Name: Krystal Biotech / Aktie / Biotechnologie & medizinische Forschung / Small Cap /
149,55 €
0,50 %
Krystal Biotech, Inc. (NASDAQ: KRYS) had its "buy" rating re-affirmed by analysts at Guggenheim. They now have a $101.00 price target on the stock.
Ratings data for KRYS provided by MarketBeat
Krystal Biotech, Inc. (NASDAQ: KRYS) had its "outperform" rating re-affirmed by analysts at William Blair.
Ratings data for KRYS provided by MarketBeat
Krystal Biotech, Inc. (NASDAQ: KRYS) is now covered by analysts at Stifel Nicolaus. They set a "buy" rating on the stock.
Ratings data for KRYS provided by MarketBeat
Krystal Biotech, Inc. (NASDAQ: KRYS) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $139.00 price target on the stock.
Ratings data for KRYS provided by MarketBeat
Krystal Biotech, Inc. (NASDAQ: KRYS) is now covered by analysts at Berenberg Bank. They set a "buy" rating and a $154.00 price target on the stock.
Ratings data for KRYS provided by MarketBeat
Krystal Biotech, Inc. (NASDAQ: KRYS) is now covered by analysts at Citigroup Inc.. They set a "buy" rating on the stock.
Ratings data for KRYS provided by MarketBeat
Krystal Biotech, Inc. (NASDAQ: KRYS) is now covered by analysts at Cantor Fitzgerald. They set an "overweight" rating and a $100.00 price target on the stock.
Ratings data for KRYS provided by MarketBeat
Krystal Biotech, Inc. (NASDAQ: KRYS) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $160.00 price target on the stock.
Ratings data for KRYS provided by MarketBeat
Krystal Biotech, Inc. (NASDAQ: KRYS) is now covered by analysts at The Goldman Sachs Group, Inc.. They set a "buy" rating and a $160.00 price target on the stock.
Ratings data for KRYS provided by MarketBeat
Krystal Biotech, Inc. (NASDAQ: KRYS) had its price target raised by analysts at Cantor Fitzgerald from $160.00 to $180.00. They now have an "overweight" rating on the stock.
Ratings data for KRYS provided by MarketBeat
Krystal Biotech, Inc. (NASDAQ: KRYS) had its "outperform" rating re-affirmed by analysts at William Blair.
Ratings data for KRYS provided by MarketBeat
Krystal Biotech, Inc. (NASDAQ: KRYS) had its price target raised by analysts at Guggenheim from $130.00 to $175.00. They now have a "buy" rating on the stock.
Ratings data for KRYS provided by MarketBeat
Krystal Biotech, Inc. (NASDAQ: KRYS) had its price target raised by analysts at Citigroup Inc. from $160.00 to $195.00. They now have a "buy" rating on the stock.
Ratings data for KRYS provided by MarketBeat
Krystal Biotech, Inc. (NASDAQ: KRYS) had its "buy" rating re-affirmed by analysts at Stifel Nicolaus. They now have a $204.00 price target on the stock, up previously from $178.00.
Ratings data for KRYS provided by MarketBeat
Krystal Biotech, Inc. (NASDAQ: KRYS) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $200.00 price target on the stock.
Ratings data for KRYS provided by MarketBeat
Neueste Beiträge
Benchmark_Co_ in Codexis Inc. diskutieren